Of problems and opportunities-How to treat and how to not treat crystallographic fragment screening data
- PMID: 36040268
- PMCID: PMC9424839
- DOI: 10.1002/pro.4391
Of problems and opportunities-How to treat and how to not treat crystallographic fragment screening data
Abstract
In their recent commentary in Protein Science, Jaskolski et al. analyzed three randomly picked diffraction data sets from fragment-screening group depositions from the PDB and, based on that, they claimed that such data are principally problematic. We demonstrate here that if such data are treated properly, none of the proclaimed criticisms persist.
Keywords: PanDDA; compositional heterogeneity; conformational heterogeneity; fragment-screening; group depositions; low-occupancy ligands.
© 2022 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Bowler MW, Svensson O, Nurizzo D. Fully automatic macromolecular crystallography: the impact of MASSIF‐1 on the optimum acquisition and quality of data. Crystallogr Rev. 2016;22:233–249.
-
- Wollenhaupt J, Barthel T, Lima GMA, et al. Workflow and tools for crystallographic fragment screening at the Helmholtz‐Zentrum Berlin. J Vis Exp. 2021;2021:1–19. - PubMed
